Drug Profile
Research programme: skin disorder therapeutics - Foamix/Galderma
Latest Information Update: 16 Mar 2020
Price :
$50
*
At a glance
- Originator Foamix; Galderma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 08 May 2014 No development reported - Preclinical for Skin disorders in Israel (Topical)
- 19 Apr 2010 Preclinical development is ongoing in Israel